Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease

Haematologica

Volumn 87, Issue 5, 2002, Pages 507-511

  Anselmo, Anna Paola ^a   Cavalieri, Elena ^a   Meloni, Giovanna ^a   Alimena, Giuliana ^a   Cantonetti, Maria ^a   Enrici, Riccardo Maurizi ^a   Tosti, Maria Elena ^a   Osti, Mattia Falchetto ^a   Gianfelici, Valentina ^a   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Autotransplant; IEV regimen; Resistant Hodgkin's disease; Salvage chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MALE; RELAPSE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; FOLLOW UP; MORTALITY; RECURRENT DISEASE; SALVAGE THERAPY; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036090648     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Treatment of MOPP resistant Hodgkin's disease with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD)
2. Treatment strategies for patients with relapsed or refractory Hodgkin's disease
3. Comparison between conventional salvage therapy and high dose therapy with autografting for recurrent or refractory Hodgkin's disease
4. Autologous stem cell transplantation for high-risk Hodgkin's disease: Improvement over time and impact of conditioning regimen
5. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non Hodgkin' lymphoma and Hodgkin's disease
6. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of BNLI randomised trial
7. Conventional salvage chemotherapy vs high-dose therapy with autograft for recurrent or refractory Hodgkin's disease patients
8. Massive chemotherapy and autologous bone marrow transplantation (ABMT) in 88 advanced resistant Hodgkin's disease patients. An update of the Italian study group
9. Autografting in lymphoma: Prospects for the future
10. Autologous bone marrow transplantaar tion for refractory or relapsed Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience using high dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation
11. Prolonged disease free survival after high dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease
12. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival
13. High dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy
14. Autotransplant for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry
15. High dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation Lymphoma Working Party
16. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group
17. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease
18. Highdose therapy and autologous stem cell transplantation for high-risk hodgkin's lymphoma: A single center experience